Paid Clinical Trials and Focus Groups by Category |
|
|
|
Conditions: Breast Cancer; Lung Cancer; Renal Cancer; Adrenal Cancer
Intervention: Drug: F-18 Paclitaxel (FPAC)
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: sunitinib malate
Sponsor: Wales Cancer Trials Unit
Recruiting - verified March 2010
Conditions: Renal Cell Cancer; Cancer
Intervention: Drug: Nelfinavir and temsirolimus
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified June 2009
Condition: Advanced Renal Cell Carcinoma
Interventions: Drug: Tivozanib; Drug: Sorafenib
Sponsor: AVEO Pharmaceuticals, Inc.
Not yet recruiting - verified February 2010
Conditions: Kidney Cancer; Renal Cell Carcinoma
Interventions: Biological: Vitespen (HSPPC-96); Biological: Vitespen (HSPPC-96)
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified February 2010
Conditions: Metastatic Renal Cell Carcinoma; Gastrointestinal Stromal Tumors
Intervention: Drug: Sunitinib malate
Sponsor: Pfizer
Not yet recruiting - verified February 2010
Condition: Renal Cell Carcinoma
Intervention: Drug: Sunitinib and Dalteparin mono and combination therapy
Sponsors: Roswell Park Cancer Institute; Pfizer
Recruiting - verified March 2010
Condition: Renal Cell Carcinoma
Intervention: Drug: Definity
Sponsors: University Health Network, Toronto; Lantheus Medical Imaging
Recruiting - verified February 2010
Condition: Carcinoma, Renal Cell
Intervention: Other: Not specified
Sponsor: Pfizer
Not yet recruiting - verified February 2010
Condition: Multiple Myeloma
Intervention: Drug: velcade
Sponsor: PETHEMA Foundation
Not yet recruiting - verified March 2010
Conditions: Adrenocortical Carcinoma; Gastrointestinal Carcinoid Tumor; Kidney Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: Seneca Valley virus-001; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified January 2010
Conditions: Pancreatic Cancer; Colorectal Cancer
Intervention: Biological: Cancer macrobead placement in abdominal cavity
Sponsor: The Rogosin Institute
Recruiting - verified March 2010
Condition: Renal Cell Carcinoma
Intervention: Drug: Aldesleukin
Sponsor: Roswell Park Cancer Institute
Recruiting - verified March 2010
Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Bionomics Limited
Recruiting - verified February 2010
Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Advanced Renal Cell Carcinoma
Interventions: Drug: tivozanib (AV-951); Drug: Sorafenib
Sponsor: AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2010
Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Drug: pazopanib hydrochloride; Radiation: fludeoxyglucose F 18
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting - verified March 2010
Condition: Carcinoma, Renal Cell
Interventions: Drug: BIBF 1120; Drug: sunitinib
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Carcinoma, Renal Cell; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-75
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Condition: Magnetic Resonance Imaging
Interventions: Drug: Gadovist (Gadobutrol, BAY86-4875); Drug: Magnevist (Gadopentetate Dimeglumine, BAY86-4882)
Sponsor: Bayer
Recruiting - verified February 2010
Condition: Cancer
Interventions: Biological: allogeneic CMV/AdV-specific cytotoxic T lymphocytes; Other: laboratory biomarker analysis
Sponsors: Baylor College of Medicine; National Cancer Institute (NCI)
Recruiting - verified December 2009
Conditions: Carcinoma, Hepatocellular; Carcinoma, Renal Cell
Intervention: Drug: Sorafenib ( Nexavar, BAY43-9006)
Sponsor: Bayer
Recruiting - verified March 2010
Conditions: Solid Tumor; Kidney Neoplasms; Advanced Renal Cell Carcinoma
Interventions: Drug: CVX-060 + sunitinib; Drug: CVX-060 + sunitinib; Drug: CVX-060 + sunitinib; Drug: CVX-060 + sunitinib; Drug: CVX-060 + sunitinib; Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified February 2010
Conditions: Renal Cell Cancer; Colorectal Cancer; GIST
Intervention: Other: Questionnaires
Sponsor: Radboud University
Recruiting - verified March 2010
Condition: Renal Cell Carcinoma
Intervention: Drug: Lenalidomide (CC-5013) in combination with sunitinib
Sponsor: Celgene Corporation
Recruiting - verified February 2010
Conditions: Kidney Cancer; Head and Neck Cancer; Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Ovarian Cancer; Esophageal Cancer; Gliomas
Intervention: Drug: 177Lu-J591
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Conditions: Neoplasms; Solid Tumors; Bone Cancer; Kidney Tumor; Neuroblastoma
Interventions: Drug: Temozolomide, Irinotecan, and SCH 717454; Drug: Vincristine, Doxorubicin, Cyclophosphamide (CAV), and SCH 717454; Drug: Ifosfamide, Etoposide (IE), and SCH 717454
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Cancer
Interventions: Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2009
Conditions: Renal Cell Carcinoma; Non-Hodgkin's Lymphoma
Intervention: Biological: MDX-1203
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: medical chart review; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: evaluation of cancer risk factors
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2009
Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Neoplasms; Pulmonary Disease, Chronic Obstructive; Heart Failure; Renal Disease
Interventions: Other: Outlook Attention Control; Other: Outlook Intervention
Sponsors: Duke University; National Institute of Nursing Research (NINR)
Recruiting - verified March 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Carcinoma, Renal Cell; Carcinoma, Renal Cell (Advanced)
Intervention: Drug: Nexavar (Sorafenib, BAY43-9006)
Sponsor: Bayer
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonneoplastic Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001; Drug: sunitinib
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Cancer
Interventions: Other: immunological diagnostic method; Other: physiologic testing
Sponsors: Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified June 2009
Condition: Cancer
Interventions: Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Procedure: allogeneic bone marrow transplantation
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified August 2009
Conditions: Advanced or Metastatic Renal Cell Carcinoma; Renal Cancer
Intervention: Drug: Sutent
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Advanced Renal Cell Carcinoma
Interventions: Drug: AMG386; Drug: Sunitinib
Sponsor: Amgen
Recruiting - verified February 2010
Condition: Advanced Renal Cell Carcinoma
Intervention: Other: Observational
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Carcinoma, Renal Cell
Interventions: Drug: axitinib; Drug: axitinib; Drug: axitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Renal Cell Carcinoma
Intervention: Other: 89Zr-Bevacizumab PET-scan
Sponsor: University Medical Centre Groningen
Recruiting - verified January 2009
Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Renal Cell Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: interferon alfa-2a
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methotrexate; Drug: tacrolimus; Genetic: polymerase chain reaction; Other: pharmacological study; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsor: Blood and Marrow Transplant Group of Georgia
Recruiting - verified June 2009
Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Kidney Cancer; Liver Cancer; Lymphoma; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: dasatinib; Drug: etoposide phosphate; Drug: ifosfamide; Genetic: microarray analysis; Genetic: western blotting; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2009
Conditions: Renal Cell Carcinoma; Gastrointestinal Stromal Tumor
Interventions: Drug: usage oral angiogenesis inhibitor; Drug: stop oral angiogenesis inhibitor
Sponsor: Radboud University
Recruiting - verified March 2010
Conditions: Carcinoma, Renal Cell; Carcinoma, Renal Cell (Advanced)
Intervention: Drug: Nexavar (Sorafenib, BAY43-9006)
Sponsor: Bayer
Recruiting - verified March 2010
Conditions: Bladder Cancer; Brain and Central Nervous System Tumors; Esophageal Cancer; Intraocular Melanoma; Kidney Cancer; Lymphoma; Melanoma (Skin); Pancreatic Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration
Sponsor: Cancer Research UK
Recruiting - verified September 2008
Condition: Cancer
Interventions: Biological: cytomegalovirus IE-1-specific cytotoxic T lymphocytes; Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes; Biological: therapeutic allogeneic lymphocytes; Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunological diagnostic method; Other: laboratory biomarker analysis
Sponsors: Milton S. Hershey Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2008
Conditions: Renal Cell Carcinoma; Non-small Cell Lung Cancer; Malignant Melanoma; Epithelial Ovarian Cancer; Colorectal Adenocarcinoma
Intervention: Biological: MDX-1105
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Conditions: Metastatic Castration-resistant Prostrate Cancer (mCRPC); Renal Cell Carcinoma (RCC); Malignant Melanoma (MEL); Non-small Cell Lung Cancer (NSCLC)
Intervention: Biological: MDX-1106
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Carcinoma, Renal Cell; Adenocarcinoma, Renal Cell; Nephroid Carcinoma; Carcinoma, Hypernephroid
Interventions: Drug: bevacizumab, RAD001(Everolimus); Drug: bevacizumab, interferon alfa-2a
Sponsors: Novartis Pharmaceuticals; Roche Pharma AG
Recruiting - verified March 2010
Condition: Carcinoma, Renal Cell
Intervention: Drug: Sunitinib Malate (SU011248)
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: imatinib mesylate; Genetic: reverse transcriptase-polymerase chain reaction; Other: confocal microscopy; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: biopsy
Sponsor: National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Kidney Cancer; Leukemia; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: dactinomycin; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: montelukast sodium; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsor: National Cancer Institute (NCI)
Recruiting - verified August 2008
Condition: Cancer
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Biological: rituximab; Drug: clofarabine; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: umbilical cord blood transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified October 2008
Condition: Cancer
Interventions: Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes; Genetic: polymerase chain reaction; Other: immunological diagnostic method; Procedure: adjuvant therapy
Sponsor: Baylor College of Medicine
Recruiting - verified June 2009
Conditions: Myeloproliferative Disorder; Urothelial Carcinoma; Cancer
Intervention: Drug: Bevacizumab, Carboplatin, Gemcitabine
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Other: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified October 2008
Condition: Renal Cell Cancer
Intervention:
Sponsors: Radboud University; Novo Nordisk
Recruiting - verified March 2010
Condition: Cancer
Interventions: Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes; Genetic: polymerase chain reaction; Other: flow cytometry; Other: immunologic technique; Other: laboratory biomarker analysis
Sponsor: Milton S. Hershey Medical Center
Recruiting - verified October 2007
Conditions: Renal Cell Carcinoma; Kidney Cancer
Interventions: Drug: Capecitabine; Drug: Gemcitabine; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; Eli Lilly and Company
Recruiting - verified March 2010
Condition: Renal Cell Carcinoma
Interventions: Drug: Temsirolimus; Drug: Sorafenib
Sponsor: Wyeth
Recruiting - verified February 2010
Conditions: Renal Cell Cancer; Kidney Cancer
Intervention: Drug: Sunitinib Malate
Sponsors: M.D. Anderson Cancer Center; Pfizer
Recruiting - verified March 2010
Condition: Kidney Cancer
Intervention: Radiation: stereotactic radiosurgery
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Solid Tumor; Urethral Cancer
Interventions: Drug: Bortezomib; Drug: Gemcitabine; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Kidney Cancer
Interventions: Procedure: conventional surgery; Radiation: stereotactic radiosurgery
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Other: counseling intervention; Other: educational intervention; Procedure: psychosocial assessment and care
Sponsor: National Cancer Institute (NCI)
Recruiting - verified December 2008
Condition: Cancer
Intervention: Drug: lithium carbonate
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Drug: temsirolimus
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Colorectal Neoplasms; Melanoma; Prostatic Neoplasms; Renal Cell Carcinoma; Neoplasms
Intervention: Drug: CP-675,206
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Kidney Cancer; Leukemia; Lymphoma; Neurotoxicity; Peripheral Neuropathy; Sarcoma
Interventions: Dietary Supplement: glutamic acid; Other: placebo
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI); Children's Oncology Group
Recruiting - verified February 2010
Conditions: Kidney Cancer; Leukemia; Lymphoma; Neurotoxicity; Peripheral Neuropathy; Sarcoma
Interventions: Dietary Supplement: glutamine; Other: placebo
Sponsor: Herbert Irving Comprehensive Cancer Center
Recruiting - verified December 2008
Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Drug: eribulin mesylate; Other: pharmacological study
Sponsors: California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Kidney Cancer
Intervention: Biological: aflibercept
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Drug: sunitinib malate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Cancer
Interventions: Other: laboratory biomarker analysis; Other: physiologic testing; Procedure: biopsy; Procedure: management of therapy complications
Sponsor: National Cancer Institute (NCI)
Recruiting - verified September 2006
Conditions: Kidney Cancer; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Pulmonary Complications; Sarcoma
Interventions: Biological: etanercept; Drug: methylprednisolone
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: CD4+CD25+ regulatory T cells; Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified September 2009
Condition: Cancer
Interventions: Procedure: music therapy; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); National Institute of Nursing Research (NINR)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Genetic: cytogenetic analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Other: questionnaire administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor
Intervention: Biological: therapeutic allogeneic lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified December 2009
Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Oral Complications; Ovarian Cancer; Pain; Sarcoma
Interventions: Procedure: management of therapy complications; Procedure: pain therapy
Sponsor: Medical College of Wisconsin
Recruiting - verified June 2009
All Categories ... Medical Conditions » ... Cancers » ... Kidney (Renal Cell) Cancer 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
